On October 25, 2023, Aligos Therapeutics, Inc. closed the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.451 USD | +8.39% |
|
-9.80% | -32.08% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.08% | 32.5M | |
+34.14% | 51.51B | |
-6.54% | 39.03B | |
+34.92% | 38.91B | |
-12.11% | 26.68B | |
+12.62% | 26.13B | |
-13.43% | 19.91B | |
+43.73% | 13.71B | |
+31.81% | 12.38B | |
-4.54% | 11.74B |
- Stock Market
- Equities
- ALGS Stock
- News Aligos Therapeutics, Inc.
- Aligos Therapeutics, Inc. announced that it has received $92.149997 million in funding from EcoR1 Capital, LLC, Deep Track Capital, LP, Armistice Capital LLC, Roche Venture Fund